FK UAD and Shandong Quanxi Biotech Explore Collaboration, A New Breakthrough in Stem Cell Therapy in Indonesia

Shandong Quanxi Biotech, a Chinese biotechnology company, is exploring collaboration opportunities in stem cell therapy with the Faculty of Medicine of Universitas Ahmad Dahlan (UAD) Yogyakarta. This collaboration is projected to be a strategic step in developing modern healthcare technology in Indonesia, especially within the vast network of Muhammadiyah universities and hospitals.

This event occurred at the Faculty of Medicine building, Kragilan Tamanan, Banguntapan Bantul, on Wednesday (18/09/24). The meeting was attended by Prof. Ir. Sunardi, S.T., M.T., Ph.D. (Vice Rector for Academic Affairs), Dr. Utik Bidayati, S.E., M.M. (Vice-Rector for Finance, Property, and General Administration), Ulaya Ahdiani (Head of the Office of Partnership and International Affairs), Afit Istiandaru, S.Pd., M.Pd. (Head of  International Partnership Affairs), as well as other leaders from the Faculty of Medicine, including the Dean, Vice Dean, Head of Department, and Deputy Head of the Department of Faculty of Medicine.

The representatives of the Shandong Quanxi Biotech You Qinyan (CEO of Quanxi) consists of Jihan Mulkan Jaya, Elisa Zhou, Oditya Norwendo, Reksoprabowo, Arofiq, Junaidi Hong Taufiqurrahman, Febri Lestanto, Rossi Attaki, Yulianto Neri Mugiono, Zhang Xiao Ling, and Lin Xiao Hui.

This collaboration is expected to strengthen the collaboration between both parties and start significant opportunities for larger research on Medicine. This data will serve as a key foundation for the development of stem cell therapy research in Indonesia. With the immense potential in the healthcare field, this partnership is expected to significantly impact the advancement of modern healthcare technology in both countries.

This momentum is also seen as a strategic effort to solidify Muhammadiyah’s role in advancing science and healthcare technology in Indonesia. Through its network of universities and hospitals, Muhammadiyah is expected to continue contributing to health innovation and research that benefits the wider community.